// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Transcriptomic analysis identifies a unique, intermittent hypoxia mediated inflammatory profile: evidence from a cross-over randomised CPAP withdrawal trial, with and without supplemental oxygen, in OSA

Christopher Turnbull - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT

Mark Dransfield - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Relationship between HLA-DQA1, -DQB1 gene polymorphism and susceptibility to pollen allergy in Russians

Bella Shamgunova - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program

Hector Ortega - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Patient engagement in a paediatric difficult asthma clinic.

Sonal Kansra - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough.

Jaclyn Smith - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gefapixant

Effects of prebiotics and synbiotics on asthma outcomes: a systematic review and meta-analysis

Neil Williams - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

IL-4

A novel point of care test for sputum sample stratification prior to the quantitative measurement of active neutrophil elastase

Darragh McCafferty - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Elaszym

Late Breaking Abstract - Trial of c-reactive protein point of care testing (CRP-POCT) for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease (COPD) in primary care

Christopher C. Butler - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Is echogenic swirling seen on ultrasound predictive of pleurodesis outcome?

Maged Hassan - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease

Amy Olson - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Understanding utilisation of Pulmonary Rehabilitation in Primary care: an online survey

Frances Early - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial

David A Lipson - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

fluticasone furoate/umeclidinium/vilanterol

Exercise capacity and response of exercise-induced bronchoconstriction to bronchodilator in preterm-born children with low lung function

Michael Cousins - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Salbutamol

Efficacy of the device in targeting tiotropium to the small airways in COPD

Martyn Biddiscombe - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Tiotropium bromide

Diagnostic delay in tuberculosis in Yorkshire & Humber, UK: 2013-16 data

Stefanie Gissing - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults

Atul Gupta - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Clinical and transcriptomic profiles of severe asthmatics with high or low expression of the glucocorticoid receptor and importin-7.

Ranga Mullegama - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Glucocorticoid

Dual bronchodilator response according to bronchitis symptoms in the FLAME study

Alexander Mackay - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

salmeterol + fluticasone

Comprehensive comparison of the repeatability of the most commonly employed tests of exercise performance for patients with stable COPD. An observational study

Theresa Harvey-Dunstan - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Copyright © 2026. QuantiNova All rights reserved